Tiger Brokers

SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98

Reuters
Mar 27
SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98
  • SpyGlass Pharma filed a Form 8-K reporting fourth-quarter and full-year 2025 results and a corporate update, including the completion of its IPO raising USD 172.5 million in gross proceeds and a Nasdaq listing.
  • Cash, cash equivalents and short-term investments were USD 107.4 million at year-end 2025, and the company said its cash position including IPO proceeds is expected to fund planned operations through 2028.
  • R&D expense rose 35.09% to USD 7.7 million in Q4 and increased 46% to USD 29.2 million for FY 2025, driven by hiring clinical and research personnel and initiating registrational Phase 3 trials for the BIM-IOL System.
  • G&A expense rose 195% to USD 5.9 million in Q4 and increased 73.24% to USD 12.3 million for FY 2025, primarily due to higher professional services and personnel.
  • Net loss widened 50% to USD 12.6 million in Q4 and increased 36.64% to USD 39.9 million for FY 2025; CEO Patrick Mooney said the company is advancing two ongoing Phase 3 BIM-IOL trials with full enrollment expected in 2027 and plans to initiate a first-in-human BIM-DRS trial in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001778922-26-000018), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10